Published in Am J Pathol on June 01, 1999
KAI1 metastasis suppressor gene is frequently down-regulated in cervical carcinoma. Am J Pathol (2001) 1.14
Differential gene expression patterns in HER2/neu-positive and -negative breast cancer cell lines and tissues. Am J Pathol (2002) 1.13
The tetraspanin superfamily member NET-6 is a new tumor suppressor gene. J Cancer Res Clin Oncol (2007) 0.86
KAI1 gene is differently expressed in papillary and pancreatic cancer: influence on metastasis. World J Gastroenterol (2000) 0.84
Down-regulation of the metastasis suppressor protein KAI1/CD82 correlates with occurrence of metastasis, prognosis and presence of HPV DNA in human penile squamous cell carcinoma. Virchows Arch (2008) 0.80
Effects of KAI1/CD82 on biological behavior of human colorectal carcinoma cell line. World J Gastroenterol (2003) 0.79
KAI1 gene expression in colonic carcinoma and its clinical significances. World J Gastroenterol (2004) 0.78
Expression of the Metastasis Suppressor KAI1 in Uveal Melanoma. J Ophthalmol (2013) 0.76
KAI1 metastasis suppressor protein in cervical cancer. Am J Pathol (2002) 0.75
Elevated KAI1 Protein Expression Identified in Malignant Melanoma. Ann Dermatol (2013) 0.75
Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res (1995) 7.42
The tetraspanin superfamily: molecular facilitators. FASEB J (1997) 4.29
KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science (1995) 3.97
Correlation of KAI1/CD82 gene expression with good prognosis in patients with non-small cell lung cancer. Cancer Res (1996) 1.59
Association of TM4SF proteins with integrins: relevance to cancer. Biochim Biophys Acta (1996) 1.51
Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss. Cancer Res (1996) 1.50
Correlation of reduction in MRP-1/CD9 and KAI1/CD82 expression with recurrences in breast cancer patients. Am J Pathol (1998) 1.46
Genomic organization of the human KAI1 metastasis-suppressor gene. Genomics (1997) 1.23
The expression of the KAI1 gene, a tumor metastasis suppressor, is directly activated by p53. Proc Natl Acad Sci U S A (1998) 1.16
Correlation of abnormal RB, p16ink4a, and p53 expression with 3p loss of heterozygosity, other genetic abnormalities, and clinical features in 103 primary non-small cell lung cancers. Clin Cancer Res (1999) 1.14
Loss of KAI1 messenger RNA expression in both high-grade and invasive human bladder cancers. Clin Cancer Res (1997) 1.04
Reduced invasive and metastatic potentials of KAI1-transfected melanoma cells. Jpn J Cancer Res (1998) 1.04
Expression of tetra-spans transmembrane family (CD9, CD37, CD53, CD63, CD81 and CD82) in normal and neoplastic human keratinocytes: an association of CD9 with alpha 3 beta 1 integrin. Br J Dermatol (1997) 1.02
Novel staging protocol for non-small-cell lung cancers according to MRP-1/CD9 and KAI1/CD82 gene expression. J Clin Oncol (1998) 1.02
KAI1, a putative marker for metastatic potential in human breast cancer. Cancer Lett (1997) 1.02
Expression of the KAI1 protein in benign prostatic hyperplasia and prostate cancer. Am J Pathol (1996) 1.02
Increased expression of highly branched N-glycans at cell surface is correlated with the malignant phenotypes of mouse tumor cells. Cancer Res (1997) 1.01
Suppression of invasive properties of colon cancer cells by a metastasis suppressor KAI1 gene. Oncogene (1998) 1.01
Reduced KAI1 expression in pancreatic cancer is associated with lymph node and distant metastases. Int J Cancer (1998) 1.01
Localization of metastasis suppressor gene(s) for prostatic cancer to the short arm of human chromosome 11. Cancer Res (1992) 1.01
Further characterization of CD82/IA4 antigen (type III surface protein): an activation/differentiation marker of mononuclear cells. Cell Immunol (1994) 0.99
Transmembrane 4 superfamily as a prognostic factor in pancreatic cancer. Int J Cancer (1998) 0.99
Frequent downregulation of the KAI1(CD82) metastasis suppressor protein in human cancer cell lines. Oncogene (1998) 0.98
Prostate cancer--biology of metastasis and its clinical implications. World J Urol (1996) 0.90
MRP-1/CD9 and KAI1/CD82 expression in normal and various cancer tissues. Int J Oncol (1997) 0.89
Location of KAI1 on the short arm of human chromosome 11 and frequency of allelic loss in advanced human prostate cancer. Prostate (1997) 0.87
Loss of tumor suppressor gene expression in high-grade but not low-grade non-Hodgkin's lymphomas. Am J Clin Pathol (1998) 0.85
KAI1/CD82 expression in nonsmall cell lung carcinoma is a novel, favorable prognostic factor: an immunohistochemical analysis. Cancer (1998) 0.84
Expression of KAI1 in paraffin-embedded normal, hyperplastic and neoplastic prostate and prostate carcinoma cell lines. Pathol Int (1998) 0.78
p53: a frequent target for genetic abnormalities in lung cancer. Science (1989) 7.51
Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. Nature (1996) 6.75
Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. Proc Natl Acad Sci U S A (1996) 4.33
A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N Engl J Med (1982) 4.04
KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science (1995) 3.97
High-resolution serum proteomic features for ovarian cancer detection. Endocr Relat Cancer (2004) 3.75
Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res (1997) 3.17
Biomarkers of oxidative stress study II: are oxidation products of lipids, proteins, and DNA markers of CCl4 poisoning? Free Radic Biol Med (2005) 3.13
New IBD genetics: common pathways with other diseases. Gut (2011) 2.95
Replication of HIV-1 in dendritic cell-derived syncytia at the mucosal surface of the adenoid. Science (1996) 2.95
PTEN/MMAC1 mutations in endometrial cancers. Cancer Res (1997) 2.89
Analysis of the cell population kinetics of transplanted tumours of widely-differing growth rate. Br J Cancer (1966) 2.88
Molecular damage in the bronchial epithelium of current and former smokers. J Natl Cancer Inst (1997) 2.83
Increased insulin sensitivity and hypoglycaemia in mice lacking the p85 alpha subunit of phosphoinositide 3-kinase. Nat Genet (1999) 2.81
Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res (2001) 2.80
Blocking of tumor promoter-induced AP-1 activity inhibits induced transformation in JB6 mouse epidermal cells. Proc Natl Acad Sci U S A (1994) 2.43
Disruption of the human SCL locus by "illegitimate" V-(D)-J recombinase activity. Science (1990) 2.40
A mathematical model of the mitotic cycle and its application to the interpretation of percentage labeled mitoses data. J Natl Cancer Inst (1966) 2.36
Microsatellite instability, mismatch repair deficiency, and genetic defects in human cancer cell lines. Cancer Res (1995) 2.35
Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice. Cancer Res (1997) 2.34
Cloning and characterization of the promoter region of human telomerase reverse transcriptase gene. Cancer Res (1999) 2.32
Splenic angiosarcoma: a clinicopathologic and immunophenotypic study of 28 cases. Mod Pathol (2000) 2.31
Malignant lymphoma of the thyroid gland: a clinicopathologic study of 108 cases. Am J Surg Pathol (2000) 2.30
A gene involved in control of human cellular senescence on human chromosome 1q. Mol Cell Biol (1994) 2.26
Inactivation of the p16 (INK4A) tumor-suppressor gene in pancreatic duct lesions: loss of intranuclear expression. Cancer Res (1998) 2.23
Deregulated expression of human c-jun transforms primary rat embryo cells in cooperation with an activated c-Ha-ras gene and transforms rat-1a cells as a single gene. Proc Natl Acad Sci U S A (1989) 2.13
Microarrays and toxicology: the advent of toxicogenomics. Mol Carcinog (1999) 2.12
Suppression of oncogene-induced transformation by a deletion mutant of c-jun. Oncogene (1993) 2.07
Dependence of asbestos- and mineral dust-induced transformation of mammalian cells in culture on fiber dimension. Cancer Res (1984) 2.03
Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosis. J Biol Chem (2000) 2.02
Application of complementary DNA microarray technology to carcinogen identification, toxicology, and drug safety evaluation. Cancer Res (1999) 2.02
Evidence for the progressive nature of neoplastic transformation in vitro. Proc Natl Acad Sci U S A (1978) 2.00
Correction of hypermutability, N-methyl-N'-nitro-N-nitrosoguanidine resistance, and defective DNA mismatch repair by introducing chromosome 2 into human tumor cells with mutations in MSH2 and MSH6. Cancer Res (1997) 1.96
Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas. J Natl Cancer Inst (2000) 1.94
Detection of frequent allelic loss on proximal chromosome 17q in sporadic breast carcinoma using microsatellite length polymorphisms. Cancer Res (1992) 1.93
Age, time and cohort factors in mortality from cancer of the cervix. J Hyg (Lond) (1973) 1.92
Mechanism of action of a dominant-negative mutant of c-Jun. Oncogene (1994) 1.81
DNA methylation analysis of the promoter region of the human telomerase reverse transcriptase (hTERT) gene. Cancer Res (1999) 1.79
Induction of gene amplification by arsenic. Science (1988) 1.72
Functional overlap in mismatch repair by human MSH3 and MSH6. Genetics (1998) 1.70
Transcriptional activation of the telomerase hTERT gene by human papillomavirus type 16 E6 oncoprotein. J Virol (2001) 1.68
TNF-alpha gene expression in macrophages: regulation by NF-kappa B is independent of c-Jun or C/EBP beta. J Immunol (2000) 1.65
optiCall: a robust genotype-calling algorithm for rare, low-frequency and common variants. Bioinformatics (2012) 1.62
A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer. Cancer Res (1998) 1.60
The transactivating domain of the c-Jun proto-oncoprotein is required for cotransformation of rat embryo cells. Mol Cell Biol (1991) 1.59
Avoided and avoidable risks of cancer. Carcinogenesis (1997) 1.58
PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. Clin Cancer Res (1998) 1.58
Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev (2007) 1.58
Identification of a gene that reverses the immortal phenotype of a subset of cells and is a member of a novel family of transcription factor-like genes. Mol Cell Biol (1999) 1.57
Possible cellular and molecular mechanisms for asbestos carcinogenicity. Am J Ind Med (1992) 1.56
Involvement of the putative hematopoietic transcription factor SCL in T-cell acute lymphoblastic leukemia. Blood (1992) 1.53
Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss. Cancer Res (1996) 1.50
Abnormalities of fragile histidine triad genomic and complementary DNAs in cervical cancer: association with human papillomavirus type. J Natl Cancer Inst (1998) 1.50
Evidence for a p53-independent pathway for upregulation of SDI1/CIP1/WAF1/p21 RNA in human cells. Mol Carcinog (1994) 1.49
Synthesis of oligodeoxyribonucleotide ethyl phosphotriesters and their specific complex formation with transfer ribonucleic acid. Biochemistry (1974) 1.49
Splenic inflammatory myofibroblastic tumor (inflammatory pseudotumor): a clinicopathologic and immunophenotypic study of 12 cases. Arch Pathol Lab Med (2001) 1.48
RASSF6 is a novel member of the RASSF family of tumor suppressors. Oncogene (2007) 1.48
Molecular genetic evidence of the occurrence of breast cancer as an integral tumor in patients with the hereditary nonpolyposis colorectal carcinoma syndrome. Cancer (1996) 1.48
Progress in understanding the molecular pathogenesis of human lung cancer. Biochim Biophys Acta (1998) 1.48
5' CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. Cancer Res (2001) 1.46
Induction by asbestos fibers of anaphase abnormalities: mechanism for aneuploidy induction and possibly carcinogenesis. Carcinogenesis (1985) 1.46
Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias. Cancer Res (1998) 1.46
Comparison of spontaneous mutation rates of normal and chemically transformed human skin fibroblasts. Cancer Res (1983) 1.45
Sickle cell anemia. Radiographics (2001) 1.44
Apoptosis and altered redox state induced by caffeic acid phenethyl ester (CAPE) in transformed rat fibroblast cells. Cancer Res (1995) 1.44
Transcription-mediated amplification is more sensitive than conventional PCR-based assays for detecting residual serum HCV RNA at end of treatment. Am J Gastroenterol (2001) 1.44
Gene expression of lung squamous cell carcinoma reflects mode of lymph node involvement. Eur Respir J (2007) 1.43
Identification of molecular markers and signaling pathway in endometrial cancer in Hong Kong Chinese women by genome-wide gene expression profiling. Oncogene (2006) 1.42
cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype. Oncogene (1999) 1.42
Biomarkers of oxidative stress study III. Effects of the nonsteroidal anti-inflammatory agents indomethacin and meclofenamic acid on measurements of oxidative products of lipids in CCl4 poisoning. Free Radic Biol Med (2005) 1.42
Mutational analysis of the PTEN gene in human uterine sarcomas. Am J Obstet Gynecol (2001) 1.41
Methylene chloride. Science (1996) 1.40
The Jun kinase/stress-activated protein kinase pathway functions to regulate DNA repair and inhibition of the pathway sensitizes tumor cells to cisplatin. J Biol Chem (1997) 1.39
The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res (1998) 1.39
Nonrandom loss of chromosome 15 in Syrian hamster tumours induced by v-Ha-ras plus v-myc oncogenes. Nature (1985) 1.39
Activation domains of L-Myc and c-Myc determine their transforming potencies in rat embryo cells. Mol Cell Biol (1992) 1.39
Allelotyping demonstrates common and distinct patterns of chromosomal loss in human lung cancer types. Genes Chromosomes Cancer (1998) 1.38
Comparison of arsenic-induced cell transformation, cytotoxicity, mutation and cytogenetic effects in Syrian hamster embryo cells in culture. Carcinogenesis (1985) 1.37
Homozygous deletions at chromosome 9p21 and mutation analysis of p16 and p15 in microdissected primary non-small cell lung cancers. Clin Cancer Res (1995) 1.37
Reactive oxygen species as double-edged swords in cellular processes: low-dose cell signaling versus high-dose toxicity. Hum Exp Toxicol (2002) 1.37
The c-Jun NH(2)-terminal protein kinase/AP-1 pathway is required for efficient apoptosis induced by vinblastine. Cancer Res (2001) 1.35
Breast cancer and environmental risk factors: epidemiological and experimental findings. Annu Rev Pharmacol Toxicol (1996) 1.35
Senescence of nickel-transformed cells by an X chromosome: possible epigenetic control. Science (1991) 1.35
Structural characterization of SIL, a gene frequently disrupted in T-cell acute lymphoblastic leukemia. Mol Cell Biol (1991) 1.34
Dominant negative mutant of c-Jun inhibits NF-AT transcriptional activity and prevents IL-2 gene transcription. J Immunol (1994) 1.34
The human papillomavirus type 16 E7 gene product interacts with and trans-activates the AP1 family of transcription factors. EMBO J (1996) 1.33
Temporal acquistion of enhanced fibrinolytic activity by syrian hamster embryo cells following treatment with benzo(a)pyrene. Cancer Res (1977) 1.31
Induction of cellular senescence in immortalized cells by human chromosome 1. Science (1990) 1.31
Direct isolation of human BRCA2 gene by transformation-associated recombination in yeast. Proc Natl Acad Sci U S A (1997) 1.30
Chromosome 5 suppresses tumorigenicity of PC3 prostate cancer cells: correlation with re-expression of alpha-catenin and restoration of E-cadherin function. Cancer Res (1995) 1.28
Mutation of MSH3 in endometrial cancer and evidence for its functional role in heteroduplex repair. Nat Genet (1996) 1.28
Occurrence of p53 gene abnormalities in gastric carcinoma tumors and cell lines. J Natl Cancer Inst (1991) 1.26
Induction of apoptosis by c-Fos protein. Mol Cell Biol (1996) 1.26
Reticulum cell neoplasms of lymph nodes: a clinicopathologic study of 11 cases with recognition of a new subtype derived from fibroblastic reticular cells. Am J Surg Pathol (1998) 1.24
Insulin-like growth factor-I: a key regulator of human cancer risk? J Natl Cancer Inst (1999) 1.24
p53 and Ki-ras gene mutations in epithelial ovarian neoplasms. Cancer Res (1993) 1.23
Normal human chromosome 11 suppresses tumorigenicity of human cervical tumor cell line SiHa. Mol Carcinog (1989) 1.23
Exploratory study of the 'weekend effect' for acute medical admissions to public hospitals in Queensland, Australia. Intern Med J (2010) 1.23
Genomic organization of the human KAI1 metastasis-suppressor gene. Genomics (1997) 1.23
Correlation of asbestos-induced cytogenetic effects with cell transformation of Syrian hamster embryo cells in culture. Cancer Res (1984) 1.21